Clinical trials: Intravenous Administration
Solid Tumor, Colon Carcinoma
PET-imaging of Two Vartumabs in Patients With Solid Tumors
VARTUTRACE is a first-in-human PET/CT molecular imaging study in patients with solid tumors. This study will investigate the biodistribution and pharmacology of two antibody fragments binding oncofetal Chondroitin Sulfate (CS).
- Conditions
- Solid Tumor, Colon Carcinoma, Rectal Carcinoma, Osteosarcoma
- Trial name
- VARTUTRACE (NCT06645808)
- Testing
- 89Zr-DFO-N-Suc-F8scFv, 89Zr-DFO-N-Suc-C9scFv, PET/CT scan
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- Var2 Pharmaceuticals
Safety, Pharmacokinetics
A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects
This is a Phase I, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Pharmacokinetics and Safety of anifrolumab following Single-Dose administration to healthy subjects
- Conditions
- Safety, Pharmacokinetics, Healthy Subjects
- Trial name
- NCT02601625
- Testing
- Anifrolumab SC injection (300mg), Anifrolumab IV infusion (300mg), Anifrolumab SC infusion (600mg)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Atrial Fibrillation
Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)
This non-interventional prospective study is a post-authorization safety study (PASS) of vernakalant conducted to collect information about normal conditions of use and appropriate dosing, and to quantify possible medically…
- Trial name
- NCT01370629
- Testing
- Vernakalant
- Where
- 6 sites in Austria, Denmark and 4 more
- Volunteers
- 2,015 people
- Sponsor
- Correvio International Sarl
Candidemia, Invasive Candidiasis
This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis
The primary objective is to estimate global response rate. Clinical, microbiological and global response rates and its 95% confidence intervals will be computed. No hypotheses will be tested.
- Trial name
- NCT00548262
- Testing
- Anidulafungin, Voriconazole
- Where
- 13 sites in Brazil, Chile and 3 more
- Volunteers
- 54 people
- Sponsor
- Pfizer
Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamic response of repeated intravenous infusions of BAN2401 in subjects with mild cognitive impairment (MCI) due to…
- Trial name
- NCT02094729
- Testing
- BAN2401 2.5 mg/kg, BAN2401 5 mg/kg, BAN2401 10 mg/kg
- Where
- 4 sites in Japan
- Volunteers
- 26 people
- Sponsor
- Eisai Co., Ltd.
Ovarian Cancer
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab…
- Trial name
- FLORENZA (NCT07059845)
- Testing
- Mirvetuximab Soravtansine, Bevacizumab, Carboplatin
- Where
- 86 sites in United States, Australia and 6 more
- Volunteers
- 400 people
- Sponsor
- AbbVie
Left Ventricle Function
Investigate the Effect of AZD1305 on Patients With Left Ventricular Dysfunction
To explore if AZD1305 compromises left ventricular performance in patients with left ventricular dysfunction
- Trial name
- NCT00748982
- Testing
- AZD1305
- Where
- Sweden
- Volunteers
- 16 people
- Sponsor
- AstraZeneca
Inflammation
Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers
The objective of the study is to investigate safety, tolerability, and pharmacokinetics of XG-102 following iv infusion of single escalating dose of 10, 40, and 80 µg/kg XG-102 to healthy male volunteers
- Trial name
- NCT01570205
- Testing
- XG-102
- Where
- Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Xigen SA
Chronic Effect of Ultraviolet Radiation on Photoaged Skin, Dermatologic Disorders
Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging
The purpose of this study is to determine whether a one-time injection of allogeneic mesenchymal bone marrow cells is safe and beneficial in the treatment of photodamage on the face.
- Trial name
- NCT01771679
- Testing
- Allogeneic Mesenchymal Bone Marrow Cells
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Stemedica Cell Technologies, Inc.
Wet Age-Related Macular Degeneration
Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration
This study evaluates the tolerability and safety of a single intravenous infusion of ACZ885. It also explores the efficacy of the compound in central macular edema and visual acuity in patients with wet age-related macular edema.
- Trial name
- NCT00503022
- Testing
- ACZ885
- Where
- 8 sites in Switzerland, United Kingdom
- Volunteers
- 20 people
- Sponsor
- Novartis
Healthy Volunteers, Rheumatoid Arthritis
A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)
The purpose of this study is to assess the safety and tolerability of CPTX2309 in healthy adult participants and adult participants with moderate to severe rheumatoid arthritis or systemic lupus erythematosus.
- Conditions
- Healthy Volunteers, Rheumatoid Arthritis, Systemic Lupus Erythematosus
- Trial name
- NCT06917742
- Testing
- CPTX2309
- Where
- 3 sites in Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Capstan Therapeutics
Glioma
A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3
This study (1438-0003) is open to adults with a tumour in the brain that is positive for the tumour marker delta-like 3 (DLL3). This study is in people with advanced cancer for whom previous treatment was not successful.
- Trial name
- NCT05916313
- Testing
- BI 764532
- Where
- 12 sites in United States, Austria and 4 more
- Volunteers
- 20 people
- Sponsor
- Boehringer Ingelheim
Dyskinesias, Movement Disorders
Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia
A Multi-Center, Phase II, Randomized, Double-Blind, Prospective, Active Placebo-Controlled Trial of Sub-Anesthetic Intravenous Infusion of Ketamine to Treat Levodopa-Induced Dyskinesia in Subjects with Parkinson's Disease.
- Conditions
- Dyskinesias, Movement Disorders, Central Nervous System Diseases, Nervous System Diseases
- Trial name
- NCT04912115
- Testing
- Ketamine, Midazolam
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- PharmaTher Inc.
Inflammatory Bowel Disease
Open-label PK Study of Iron Isomaltoside 1000 (Monofer) Administered by 500 mg IV Injection or 1000 mg IV Infusion to Patients With Inflammatory Bowel Disease
The purpose of this study is to assess the pharmakokinetic properties of higher doses (500 mg and 1000 mg) of Monofer(R)in patients suffering from inflammatory bowel disease
- Trial name
- NCT01213680
- Testing
- Monofer (iron isomaltoside 1000), Monofer
- Volunteers
- 16 people
- Sponsor
- Pharmacosmos A/S
Idiopathic Pulmonary Fibrosis
A Trial of SHR - 1906 in Healthy Subjects
This study is a phase 1 single dose escalation study of SHR-1906 in healthy subjects. The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of SHR-1906 in healthy subjects.
- Trial name
- NCT04986540
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
COVID19 Pneumonia
Clinical Trial to Investigate the Efficacy and Safety of NuSepin® in COVID-19 Pneumonia Patients
A randomized, double blind, placebo-controlled, phase 2 clinical trial to investigate the efficacy and safety of 2 doses of NuSepin® intravenous infusion in COVID-19 pneumonia patients
- Trial name
- NCT04565379
- Testing
- NuSepin® 0.1 mg, NuSepin® 0.2 mg
- Where
- 5 sites in Romania
- Volunteers
- 64 people
- Sponsor
- Shaperon
Atrophy, Geographic
Pharmacokinetic (PK) Study of GSK933776 in Healthy Volunteers
This study is intended to enable a possible transition to intramuscular (IM) or subcutaneous (SQ) administration for subsequent studies with GSK933776 by characterizing the safety, tolerability, PK and pharmacodynamic profiles…
- Trial name
- NCT02033668
- Testing
- GSK933776 for SQ administration, GSK933776 for IM administration, GSK933776 for IV administration
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Systemic Lupus Erythematosus
Japanese phase1 Study of Belimumab (IV vs SC)
This study is an open-label, randomized, 2 parallel group, single dose study in healthy Japanese males to assess the pharmacokinetics and safety/tolerability of single intravenous administration and single subcutaneous…
- Trial name
- NCT01516450
- Testing
- GSK1550188 IV, GSK1550188 SC
- Where
- Japan
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QAX576 in Asthma Patients
This study is designed to investigate the safety and tolerability of multiple doses of QAX576 in controlled or partially controlled asthma patients.
- Trial name
- NCT00940160
- Testing
- QAX576
- Where
- 3 sites in Russia, United Kingdom
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Autism, Autistic Disorder
Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism
The purpose of this study is to determine if human immunoglobulin given by mouth twice a day is effective in treating the persistent gastrointestinal (GI) problems such as diarrhea, constipation, abdominal pain, and bloating, in…
- Conditions
- Autism, Autistic Disorder, Child Development Disorders, Pervasive, Gastrointestinal Diseases
- Trial name
- NCT00110708
- Testing
- Oralgam (human immunoglobulin)
- Where
- 22 sites in United States
- Volunteers
- 120 people
- Sponsor
- PediaMed Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.